- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00248521
17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (17-DMAG) in Treating Patients With Metastatic Solid Tumors or Tumors That Cannot Be Removed By Surgery
A Cancer Research UK Phase I Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of 17-Dimethylaminoethyl-amino-17-Demethoxygeldanamycin (17-DMAG) Given as a Once Weekly Infusion in Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
PURPOSE: This phase I trial is studying the side effects and best dose of 17-DMAG in treating patients with metastatic solid tumors or tumors that cannot be removed by surgery.
연구 개요
상세 설명
OBJECTIVES:
Primary
- Determine the maximum tolerated dose, dose-limiting toxicity, and recommended phase II dose of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in patients with unresectable or metastatic solid tumors.
- Determine the feasibility, safety, and toxicity profile of this drug in these patients.
Secondary
- Determine the clinical pharmacokinetic profile of this drug in these patients.
- Determine tumor response in patients treated with this drug.
- Determine the biologically effective dose.
OUTLINE: This is an open-label, non-randomized, dose-escalation, multicenter study.
Patients receive 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) IV over 1 hour on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of 17-DMAG until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. An additional 10 patients are treated at the MTD.
After completion of study treatment, patients are followed for 28 days.
PROJECTED ACCRUAL: Approximately 25-35 patients will be accrued for this study within 12-18 months.
연구 유형
등록 (예상)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
England
-
Sutton, England, 영국, SM2 5PT
- Royal Marsden - Surrey
-
Sutton, England, 영국, SM2 5NG
- Institute of Cancer Research - Sutton
-
-
Northern Ireland
-
Belfast, Northern Ireland, 영국, BT8 8JR
- Belfast City Hospital Trust Incorporating Belvoir Park Hospital
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed solid tumor
- Unresectable or metastatic disease
- Standard curative or palliative measures do not exist OR are no longer effective OR patient refused such measures
- No known brain metastases
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- ECOG 0-1
Life expectancy
- More than 12 weeks
Hematopoietic
- Absolute neutrophil count > 1,500/mm^3
- Platelet count ≥ 100,000/mm^3
- Hemoglobin ≥ 9.0 g/dL
Hepatic
- Bilirubin normal
- ALT and AST ≤ 1.5 times upper limit of normal
- No chronic liver disease
- Hepatitis B or C negative
Renal
- Creatinine normal OR
- Creatinine clearance normal
Cardiovascular
- No symptomatic New York Heart Association class III-IV cardiac disease
- No myocardial infarction within the past year
- No active ischemic heart disease within the past year
- No poorly controlled angina
- No uncontrolled dysrhythmia or dysrhythmias requiring antiarrhythmic drugs
- No transient ischemic attack
- No stroke
- No peripheral vascular disease
- No congenital long QT syndrome
- No history of serious ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation ≥ 3 beats in a row)
- QTc < 450 msec (for men) and 470 msec (for woman)
- LVEF > 40% by MUGA
- No left bundle branch block
Pulmonary
No symptomatic pulmonary disease requiring medication, including any of the following:
- Dyspnea with or without exertion
- Paroxysmal nocturnal dyspnea
- Oxygen requirement
- Significant pulmonary disease (e.g., chronic obstructive/restrictive pulmonary disease
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception 4 weeks before, during, and for 6 months after completion of study treatment
- No known HIV positivity
- No other malignancy within the past 5 years except adequately treated cone biopsied carcinoma in situ of the cervix or basal cell or squamous cell skin cancer
- No ongoing or active infection
- No diabetes mellitus (with evidence of severe peripheral vascular disease or ulcers)
- No psychiatric illness or social situation that would preclude study compliance
- No other uncontrolled illness
PRIOR CONCURRENT THERAPY:
Biologic therapy
- More than 4 weeks since prior immunotherapy
- Concurrent epoetin alfa allowed
Chemotherapy
- More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
- No prior 17-N-allylamino-17-demethoxygeldanamycin (17-AAG)
Endocrine therapy
- More than 4 weeks since prior endocrine therapy
- Concurrent luteinizing hormone-releasing hormone analogues for androgen-insensitive prostate cancer and rising prostate-specific antigen allowed
Radiotherapy
- More than 4 weeks since prior radiotherapy (except for palliative treatment)
- No prior irradiation field that potentially included the heart (e.g., mantle)
Surgery
- Not specified
Other
- Recovered from all prior therapy
- Concurrent bisphosphonates allowed
- At least 5 half-lives since prior and no concurrent medication that prolong QTc
- No other concurrent anticancer or investigational agents
- No concurrent grapefruit juice
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 마스킹: 없음(오픈 라벨)
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
---|
Recommended phase II dose of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) at 28 days after treatment
|
2차 결과 측정
결과 측정 |
---|
Heat shock protein 90 (HSP90) client protein and co-chaperone changes up to 29 days after treatment
|
Tumor response by RECIST criteria every 6 weeks while on study
|
Clinical pharmacokinetic profile established during the first course of treatment
|
공동 작업자 및 조사자
수사관
- 연구 의자: Ian R. Judson, MA, MD, FRCP, Institute of Cancer Research, United Kingdom
간행물 및 유용한 링크
일반 간행물
- Pacey SC, Wilson RH, Walton M, et al.: A phase I trial of the heat shock protein 90 (HSP90) inhibitor alvespimycin (17-dimethylaminoethylamino-17-demethoxygeldanamycin 17-DMAG) administered weekly, intravenously, to patients with advanced solid tumors. [Abstract] American Association for Cancer Research: Molecular Targets and Cancer Therapeutics, October 22-26, 2007, San Francisco, CA A-PR-6, 2007.
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (예상)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- ICR-PH1/102
- CDR0000442402 (레지스트리 식별자: PDQ (Physician Data Query))
- NCI-6547
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
알베스피마이신 염산염에 대한 임상 시험
-
Haihe Biopharma Co., Ltd.Shanghai Institute of Materia Medica, Chinese Academy of Sciences완전한
-
Torrent Pharmaceuticals Limited완전한
-
Bing He모집하지 않고 적극적으로
-
University Hospital Southampton NHS Foundation...University of Southampton빼는
-
Torrent Pharmaceuticals Limited완전한
-
Aziende Chimiche Riunite Angelini Francesco S.p.AZak-Pharma Dienstleistung Ges.m.b.H.완전한
-
Xian-Janssen Pharmaceutical Ltd.완전한